Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study

Rachel F. Buckley, PhD,1,2,3† Adrienne O'Donnell, BA,4,5† Emer R. McGrath, MB, PhD,5,6
Heidi I.L. Jacobs, PhD,7,8 Cristina Lois, PhD,7 Claudia L. Satizabal, PhD,5,9,10
Saptaparni Ghosh, PhD,5 Zoe B. Rubinstein, BA,7 Joanne M. Murabito, MD,10
Reisa A. Sperling, MD,1,2 Keith A. Johnson, MD,2,7 Sudha Seshadri, MD,5,9,10† and
Alexandra S. Beiser, PhD4,5,10‡

Objective: Women have a higher lifetime risk of Alzheimer’s disease (AD) than men. Among cognitively normal (CN) older adults, women exhibit elevated tau positron emission tomography (PET) signal compared with men. We explored whether menopause exacerbates sex differences in tau deposition in middle-aged adults.

Methods: 328 CN participants from the Framingham Study (mean age = 57 years (±10 years), 161 women, of whom, 104 were post-menopausal) underwent tau and β-amyloid (Aβ)-PET neuroimaging. We examined global Aβ-PET, and tau-PET signal in 5 regions identified a priori as demonstrating significant sex differences in older adults (in temporal, inferior parietal, middle frontal, and lateral occipital regions). We examined sex and menopause status-related differences in each region-of-interest, using linear regressions, as well as interactions with Aβ and APOEε4 genotype.

Results: Women exhibited higher tau-PET signal (p < 0.002), and global Aβ-PET (p = 0.010), than men in inferior parietal, rostral middle frontal, and lateral occipital regions. Compared with age-matched men, post-menopausal women showed significantly higher tau-PET signal in parieto-occipital regions (p < 0.0001). By contrast, no differences in tau-PET signal existed between pre-menopausal women and men. Aβ-PET was not associated with menopausal status or age. Neither Aβ-PET nor APOEε4 status moderated sex or menopause associations with tau-PET.

Interpretation: Clear divergence in tauopathy between the sexes are apparent approximately 20 years earlier than previously reported. Menopause status moderated sex differences in Aβ and tau-PET burden, with tau first appearing post-menopause. Sex and menopause differences consistently appeared in middle frontal and parieto-occipital regions but were not moderated by Aβ burden or APOEε4, suggesting that menopause-related tau vulnerability may be independent of AD-related pathways.
Women demonstrate an elevated risk for progression to dementia compared to men, particularly among those at greater genetic risk of sporadic Alzheimer’s disease (AD) dementia. Women also have a higher risk of elevated AD-related pathology, specifically tau, and elevated levels of cerebrospinal fluid (CSF) total tau in apolipoprotein ε4 (APOEε4) carriers relative to men. Specifically, regions of the rostral middle frontal, inferior parietal, temporal, and lateral occipital cortices have been implicated as sites of sex-differentiated tau vulnerability. In those with abnormal levels of Aβ, however, women also exhibit higher tau-PET signal in regions of the medial temporal lobe. As such, it is clear that both Aβ-relevant and Aβ-independent sex differences exist in tau deposition in older adults.

Hormonal changes during menopause have been proposed as a rationale for the appearance of sex differences in AD pathology and clinical progression. A reduction in circulating endogenous 17β-estradiol is associated with a proliferation of AD pathology in animal models. In humans, the later stages of menopause have consistently shown higher tau positron emission tomography (PET) signal relative to men, and elevated levels of cerebrospinal fluid (CSF) total tau in apolipoprotein ε4 (APOEε4) carriers relative to men. Specifically, regions of the rostral middle frontal, inferior parietal, temporal, and lateral occipital cortices have been implicated as sites of sex-differentiated tau vulnerability. In those with abnormal levels of Aβ, however, women also exhibit higher tau-PET signal in regions of the medial temporal lobe. As such, it is clear that both Aβ-relevant and Aβ-independent sex differences exist in tau deposition in older adults.

Methods

**Participants.** A total of 328 cognitively normal adults (age = 57(SD 10), range = 32 to 88, women = 161(49%), post-menopausal women = 104 (65% of all women)) from the Framingham Study 2nd (Gen 2) and 3rd (Gen 3) generation cohorts underwent a 18F-Flortaucipir (FTPI-PET) and/or 11C-Pittsburgh Compound-B (PiB)-PET scan (see https://github.com/rfbuckley/FHS_menopause for participant flow chart). Sex was categorized on the basis of self-report. In this cross-sectional study, 94% of Aβ-PET and tau-PET scans occurred on the same day, and all occurred within 6 months of each other. We conducted the PET neuroimaging procedures for this study under the ethical guidelines stipulated by the Massachusetts General Brigham Human Research Committee, and written consent was obtained in each cohort.

**Menopause information.** Menopause included those who underwent natural or surgically induced menopause. Women who answered the following question “What is the best way to describe your periods?” with ‘Not stopped’, ‘Periods stopped due to pregnancy, breast feeding, or hormonal contraceptive’, ‘Periods stopped due to low body weight, heavy exercise, or due to medication or health condition such as thyroid disease, pituitary tumor, hormone imbalance, stress’, ‘Periods stopped for less than 1 year’, or ‘Periods stopped, but now have periods induced by hormones’ were categorized as pre-menopausal. Those who answered the question with “Periods stopped for 1 year or more” (in Gen 2 and Gen 3 cohorts) or “definitely menopausal” (Gen 2 cohort) were categorized as post-menopausal. Age-at-menopause was calculated with the item, “Age when periods stopped”; for the purposes of the current study, this variable was dichotomized at 50 years of age and treated as younger age vs. older age at menopause. Data on menopausal status and age-at-menopause were collected a median of 1 year (inter-quartile range: 0.5–2.6) from the most recent PET scan.

**Magnetic Resonance Imaging.** Structural T1-weighted anatomical images were acquired using a Philips 3T Achieva [repetition time (TR), 6,800 ms; echo time (TE), 3.1 ms; angle, 9°; voxels, 0.98 × 0.98 × 1.2 mm]. Images were processed with FreeSurfer version 6.0 to identify gray-white as well as pial surfaces and produce automatic Desikan-Killany cortical and subcortical region of interest (ROI)
parcellations, with quality control measures published previously.²⁷

**PiB Positron Emission Tomography.** The PiB-PET acquisition parameters have been published previously.²⁸,²⁹ In brief, distribution volume ratios (DVRs) were computed using Logan plotting techniques 40–60 minutes post injection. PET images were co-registered to the corresponding T1 image (SPM12), and FreeSurfer-derived ROIs were sampled. A global Aβ-PET composite was computed from a weighted average within a large aggregate cortical ROI consisting of precuneus, rostral anterior cingulate, medial orbitofrontal, superior frontal, rostral middle frontal, inferior parietal, inferior temporal, and middle temporal (termed FLR) regions. This FLR composite was referenced to cerebellar gray, and log-transformed for normality. When Aβ-PET was examined as a predictor, we divided the distribution into quintiles to address any non-linear associations with tau-PET (see Model 5). PiB and FTP scans were acquired from 2 cameras: the 5-ring GE Discovery MI³⁰ (n = 109) and the Siemens ECAT HR+ (n = 219). To harmonize data across these cameras, GE Discovery images were smoothed with a 6 mm Gaussian filter. Data were not partial volume corrected.

**FTP Positron Emission Tomography.** FTP-PET, formerly AV1451 or T807, acquisition parameters have been published.²⁸ Standard uptake volume ratios (SUVrs) were calculated from images acquired 80–100 mins post-injection and referenced to cerebellar gray.²⁹ Five tau ROIs were examined as regions implicated in preclinical AD (entorhinal and inferior temporal),²⁹ and those that demonstrate large sex differences in CN older adults (entorhinal, rostral middle fronto, inferior parietal, and lateral occipital cortices).³⁰,³¹,³²,³³,³⁴ Primary models involved data that were not partial volume corrected; however, partial volume corrected results are also reported. Partial volume correction was conducted using Geometric Transfer Matrix (GTM) method.³¹

**Statistical analyses.** Analyses were run in SAS version 9.4. We first examined demographic differences between the sexes and by menopausal status using t-tests and chi-squared tests of independence (Fisher’s exact p-value reported if cell n < 5) for continuous and categorical variables, respectively. Our primary aims were investigated using a series of linear regression models that adjusted for age at PET and type of PET camera. First, the main effect of sex was examined in association with Aβ and tau-PET

### TABLE 1. Demographic Comparisons Between the Sexes

| Sex          | Women | Men   | p    |
|--------------|-------|-------|------|
| N            | 161   | 167   |      |
| Age at PET, mean (SD) | 57 (10) | 58 (10) | 0.45 |
| Education, n (%) |       |       | 0.30 |
| ≤HS degree   | 12 (7%) | 21 (12%) |      |
| Some college | 45 (28%) | 43 (26%) |      |
| ≥College degree | 104 (65%) | 103 (62%) |      |
| APOEε4 positive, n (%) | 36 (23%) | 38 (24%) | 0.86 |
| Discovery GE camera n (%) | 58 (36%) | 51 (31%) |      |
| White n (%)  | 161 (100%) | 167 (100%) |      |

FIGURE 1: Multi-panel histogram/scatterplots of entorhinal, rostral middle frontal, inferior parietal and lateral occipital (unadjusted, raw scores) by (A) sex and (B) sex across the age span.
signal. In women only, we then tested the association of menopausal status (pre-menopause versus post-menopause) with both Aβ and tau-PET signal. Furthermore, in post-menopausal women only, we explored the association of age-at-menopause with PET signal. Chronological age is an inherent confound of menopause status as well as one of the strongest risk factors for abnormal AD biomarkers. As such, it is an important, and yet non-trivial, task to try to extricate the menopause status effect from the age effect. Unfortunately, due to the almost universal age at menopause (50 years of age), we found only minimal overlap in the current age of women considered to be pre-menopausal and post-menopausal. Due to this issue, we decided to instead use age-matched males as a control comparison against the pre-menopausal and post-menopausal women. We paired pre- and post-menopausal women with age- and camera-matched men, using a 1-year caliper matching scheme for age. This pairing, which we refer to as ‘menopausal status-matched’ groups, resulted in 32 men matched to pre-menopausal women and 69 men matched to post-menopausal women. This analysis was intended to provide a different control to account for pre-menopausal women being significantly younger than post-menopausal women.

As an additional analysis to explore the potential age confound, we replaced the menopausal status-matched group with a group that split by age above and below 50 years (the average age-at-menopause in the population). Finally, in exploratory analyses, we investigated the moderating impact of Aβ and APOEε4 status on the association between sex or menopause status on PET signal. In all analyses, global Aβ-PET and the 5 tau-PET regions were examined as dependent variables in separate models. Model

### TABLE 2. Association Between Sex and Global Aβ-PET and Regional Tau-PET Signal (SDUs)

|                      | Model 1 | Model 2 | Model 3 |
|----------------------|---------|---------|---------|
|                      | Sex (reference = men) | Menopause Status Among Women | Menopause Age (reference = <50 years) |
| β (SE) | p       | β (SE) | p       | β (SE) | p       |
| Aβ-PET DVR          | N = 323 | N = 160 | N = 100 |
| Global FLR<sup>a</sup> | 0.274 (0.101) | 0.010<sup>a</sup> | −0.176 (0.235) | 0.454 | −0.082 (0.234) | 0.728 |
| Tau-PET SUVr        | N = 259 | N = 134 | N = 84  |
| [Entorhinal]        | −0.001 (0.127) | 0.995 | −0.244 (0.268) | 0.365 | −0.106 (0.244) | 0.665 |
| Inf temporal        | −0.024 (0.120) | 0.839 | −0.174 (0.242) | 0.473 | −0.139 (0.210) | 0.511 |
| Inf parietal        | 0.452 (0.103) | <0.0001<sup>b</sup> | 0.256 (0.218) | 0.242 | −0.271 (0.198) | 0.175 |
| Inf parietal        | 0.644 (0.120) | <0.0001<sup>b</sup> | 0.193 (0.261) | 0.261 | −0.486 (0.238) | 0.045 |
| Lat occipital       | 0.292 (0.093) | 0.002<sup>b</sup> | 0.327 (0.200) | 0.103 | −0.407 (0.184) | 0.030 |

Note: Each row denotes a different linear regression model adjusted for age at PET scan and camera.

<sup>a</sup>Log transformed for normality; p < 0.05 is bolded.

<sup>b</sup>Indicates FDR-corrected p < 0.05.

FLR = frontal, lateral temporoparietal and retrosplenial regions; Inf = inferior; Lat = lateral; Mid = middle.

### TABLE 3. Demographic Comparisons Between Menopause Groups Among Women

| Menopause group | Pre | Post | p     |
|-----------------|-----|------|-------|
| N               | 57  | 104  |       |
| Age at PET, mean (SD) | 48 (6) | 62 (7) | <0.0001 |
| [min, max]      | [34–63] | [42–81] |       |
| Age at menopause | –   | 49 (5) |       |
| Education, n (%) | 4 (7%) | 8 (8%) | 0.08  |
| ≤HS degree      | 10 (18%) | 35 (33%) |       |
| Some college    | 43 (75%) | 61 (59%) |       |
| APOEε4 positive, n (%) | 12 (22%) | 24 (24%) | 0.81  |
| Discovery GE camera n (%) | 16 (28%) | 42 (40%) |       |
## TABLE 4. Demographic Comparisons Between Matched Groups

| Matched group | Pre-menopausal Cases (women) | Pre-menopausal Controls (men) | Post-menopausal Cases (women) | Post-menopausal Controls (men) |
|---------------|-----------------------------|-------------------------------|-------------------------------|-------------------------------|
|               | N = 32                      | N = 32                        | N = 69                        | N = 69                        |
| Age at PET, mean (SD) | 47 (4)                      | 47 (5)                        | 58 (5)                        | 58 (5)                        |
| Education, n (%)       |                             | 0.27                          |                               |                               |
| ≤HS degree            | 4 (13%)                     | 1 (3%)                        | 4 (6%)                        | 13 (19%)                      |
| Some college          | 8 (25%)                     | 6 (19%)                       | 29 (42%)                      | 16 (23%)                      |
| ≥College degree       | 20 (62%)                    | 25 (78%)                      | 36 (52%)                      | 40 (58%)                      |
| APOEε4 positive, n (%)| 4 (13%)                     | 11 (37%)                      | 19 (28%)                      | 15 (22%)                      |

## TABLE 5. Interaction Between Sex and Matched-Menopause Status on Tau-PET Signal Followed by Stratification by Matched Menopause Status (SDUs)

| Outcome Variable | Model 4 | Strata: PET ~ sex + education + APOEε4 status, with men matched to pre-menopause (n = 32 men matched to n = 32 women)/post-menopause (n = 69 men matched to 69 women, but missing APOEε4 status reduced the group size); p < 0.05 is bolded. |
|------------------|---------|---------------------------------------------------------------------------------|
|                  | Interaction Between Sex and Matched-Menopause | Association Between Sex (women are referent) and tau-PET in Strata\(a\) |
|                  | p       | \(\beta\) (SE) | p          |
| Tau-PET SUVr N = 202 | N/A     | N/A | N/A          |
| Entorhinal       | 0.945   | N/A | N/A          |
| Pre-meno (N = 61) | 0.600   | N/A | N/A          |
| Post-meno (N = 134) | N/A     | N/A | N/A          |
| Inferior temporal | 0.050   | N/A | N/A          |
| Pre-meno (N = 61) | -0.047 (0.198) | 0.814 | N/A          |
| Post-meno (N = 135) | -0.588 (0.162) | 0.0004\(b\) | N/A          |
| Rostral middle frontal | 0.058   | N/A | N/A          |
| Pre-meno (N = 61) | -0.330 (0.234) | 0.163 | N/A          |
| Post-meno (N = 135) | -0.829 (0.170) | <0.0001\(b\) | N/A          |
| Lateral occipital | 0.038\(b\) | N/A | N/A          |
| Pre-meno (N = 61) | 0.078 (0.201) | 0.699 | N/A          |
| Post-meno (N = 135) | -0.499 (0.165) | 0.003\(b\) | N/A          |

Note: Each section contains a different interaction model, and subsequent stratification models if the interaction was significant; N/A = Not applicable, stratification only applicable when interaction \(p\)-value <0.10.

\(a\)Strata: PET ~ sex + education + APOEε4 status, with men matched to pre-menopause (n = 32 men matched to n = 32 women)/post-menopause (n = 69 men matched to 69 women, but missing APOEε4 status reduced the group size); \(p\) < 0.05 is bolded.

\(b\)Indicates FDR-corrected \(p\) < 0.05.
estimates in tables are reported as standard deviation units (SDUs), although sex differences are reported in-text using unstandardized PET DVR or SUVr units. We set overall $\alpha = 0.05$ and adjusted for multiple comparisons using false discovery rate (FDR) correction (results $p < 0.05$ reported for interest). In each table, we report raw $p$-values and indicate FDR-corrected $p$-values below 0.05. We report raw $p$-values in text. We conducted the FDR correction separately for all analyses in each table, such that $p$-values are corrected for the number of analyses presented together. Analyses are listed below for clarity:

Model 1: PET ~ Sex (women vs. men) + current age + camera.
Model 2: PET ~ Menopause status (post-menopausal women vs. pre-menopausal women) + current age + camera.

Model 3: PET ~ (Age-at-Menopause<50 vs. Age-at-Menopause≥50) + current age + camera (post-menopausal women only).
Model 4: PET ~ Sex * menopausal status-matched group + current age + camera.
Model 4A: PET ~ Sex * </> 50 years-matched group + current age + camera.
Model 5: PET ~ Risk modifier (Aβ OR APOE ε4) * Group (sex OR menopause status) + current age + camera.

Results

Sex differences in PET signal. No demographic differences were found by sex (see Table 1). Women exhibited higher tau-PET signal in the inferior parietal, rostral middle frontal...
and lateral occipital regions than men (β = ~0.3–0.6, p < 0.002; see Fig 1 and Table 2). Women also demonstrated higher global Aβ-PET signal (β = 0.3, p = 0.010).

Using PVC data, we found the pattern of effects to remain largely the same, except in the lateral occipital region where the difference became attenuated (p = 0.90).

Menopausal status, age-at-menopause and PET signal. Post-menopausal women were older than pre-menopausal women (see Table 3). No relationship was found between current age at PET scan and age-at-menopause (rho = 0.10, p = 0.34). We found no main effect of menopause status on global Aβ-PET signal or regional tau-PET signal in women (see Table 2). Constricting the age range to those aged between 50–60 years of age in both groups resulted in a similar pattern of effects. In those who reported age-at-menopause below 50 years (n = 40), we found numerically higher tau-PET signal in the rostral middle frontal (p = 0.05) and lateral occipital regions (p = 0.03) relative to those with later age-at-menopause (n = 61), although these results did not survive FDR correction. Examining PVC data did not change the direction of these findings.

Sex-by-menopause-matched group interaction on PET signal. Pre-menopausal women showed slightly lower APOE ε4 carriersonship to age-matched men, and post-menopausal women showed slightly higher levels of education than age-matched males (see Table 4). As such, we adjusted these models with APOE ε4 status and years of education. Menopause status moderated the association between sex and tau-PET signal in the inferior parietal and lateral occipital regions (p = 0.01), as well as the rostral middle frontal region (p = 0.02; see Table 5). Using stratification models, post-menopausal women exhibited higher signal than matched men (β = ~−0.5–0.9,
No differences in tau-PET signal were found between pre-menopausal women and either matched-group of men. Examining PVC data resulted in an attenuated effect in the lateral occipital region; however, the pattern of findings in the other regions were unaffected. To explore the confound of age, we also found women over 50 years of age at the time of PET scan exhibited higher levels of tau-PET signal in both regions than matched men. Women younger than 50 years at PET scan did not exhibit differences in tau-PET signal relative to either matched group of men (Table 6).

**Discussion**

Our study examined the influence of sex and menopause status on global Aβ and regional tau-PET signal. Relative to age-matched men, post-menopausal women exhibited higher levels of Aβ and regional tau, with differences in tau-PET signal appearing in inferior parietal and lateral occipital regions. By contrast, no difference was found between pre-menopausal women and either age-matched group of men, supporting the notion that the menopause transition is a critical time in which tau deposition appears to diverge between the sexes. Post-menopausal women with early onset (below 50 years) showed numerically elevated levels of tau-PET burden in these regions. Chronological age is strongly associated with PET markers of both Aβ and tau in clinically unimpaired older adults, and we also found that women aged over 50 showed higher tau-PET signal in the same regions relative to women aged under 50 and both groups of matched men. These findings signal a critical watershed period of tau vulnerability in women that occurs around the time of menopause. Examining the menopause transition with tau is confounded by age. As such, these findings must also be interpreted within the milieu of other midlife risk profiles that come to the fore during the menopausal transition, such as increased risk for metabolic syndrome and midlife vascular risk exposure. For instance, women are at greater risk of mid-life diabetes, obesity and hypertension, which has considerable impact on vascular-related cognitive dysfunction.

We found sex differences in regional tau deposition in individuals approximately 20 years younger than those included in prior studies reporting sex differences. Our findings replicate recent work in a diverse sample of later middle-aged individuals who also reported sex differences in cortical tau deposition independent of Aβ burden.
extend these findings by reporting Aβ-independent sex differences in regional tau-PET deposition in areas not typically found to have early AD-related tau deposition.7,21,29 We found no sex by APOEε4 or sex by Aβ-PET interactions associated with tau-PET signal in any of our a priori regions, supporting the hypothesis that sex differences in these regions may not necessarily be influenced by AD-related processes. An important caveat to note is the smaller samples sizes when considering these interactions. In our previous findings, sex by Aβ-PET effects on tau-PET signal were confined to the temporal lobe,8 suggesting that perhaps 2 levels of sex dimorphic tau pathways exist: 1 exacerbated by Aβ processes, and the other driven by other pathological pathways. Unlike previous findings, we did not see any sex by Aβ-PET associations with inferior temporal tau.8,16 A recent cohort of late middle-aged adults found higher levels of middle and inferior temporal tau in women,39 but also no interaction between sex and Aβ on regional tau, suggesting that sex by Aβ interactions on tau deposition may appear later in life. We found elevated levels of global Aβ-PET signal in women, supporting previous findings amongst middle aged adults.22 We did not find any menopause status associations with Aβ-PET, sitting in contrast to prior studies21,22 that found post-menopausal women exhibited higher global Aβ load, lower white matter integrity, regional hypometabolism, and reduced gray matter volume relative to pre-menopausal women. The age range in our study was greater, which may have obscured associations with Aβ-PET, as sex differences in Aβ-PET do not traditionally appear in older adults.

A question remains as to the rationale behind sex differences in neocortical tau-PET signal in middle-aged adults. Braak staging of tau deposition10 places the appearance of neurofibrillar tangles in these regions at latter stages (Braak stages V-VI), when cognitive impairment is apparent.41 Tau-PET signal in the lateral occipital region in preclinical AD has become of particular interest to the field. Most commonly, posterior cortical atrophy patients display a characteristic pattern of lateral occipital tau-PET signal.42 Some studies report an over-representation of women by up to 50% in the PCA patient group,43,44 although this is not necessarily reflected by estimated prevalence rates.45 It is possible, however, that there may be elevated sex-specific risk for a “preclinical” PCA pathological profile. Early onset AD dementia cases characterized by prominent visuospatial dysfunction also show significant burden in occipital regions relative to age-matched controls.46

It is unlikely, however, that sex differences in these regions are highlighting preclinical stages of these rarer forms of AD. In a recent data-reduction of voxel-wise tau-PET data across a range of clinical unpaired and impaired individuals, a distinctive cluster of lateralized lateral occipital signal was reported in those with high Aβ burden.47 Other studies of preclinical AD have also shown elevated tau-PET signal in inferior occipital and inferior parietal regions.39 As such, there is mounting evidence of lateral occipital and inferior parietal tau-PET signal appearing in cases of preclinical AD. The biological relevance of sex differences in tau deposition in these regions, however, remains unclear. It is possible, however, that sex-specific regional tau vulnerability outside the medial temporal lobe is driven by sex hormonal or sex chromosomal factors, or that rapid tau proliferation beyond the medial temporal region is a byproduct of a post-menopausal environment (hormonal, vascular, metabolic, etc).

These findings introduce a wider implication of what it means to be “tau abnormal” for women relative to men. Given the mounting evidence across multiple independent studies of higher tau in women across cortical regions,6,7,11,12,16,39 even in middle age,39 this raises the question of how to understand and interpret tau deposition in women relative to men in observational cohorts as well as clinical trials. At a broad level, this has implications for how we understand tauopathies and the extent to which certain tau species propagate in a sex-specific manner. From a pragmatic standpoint, defining individuals with “high tau” in the A/T/N model48 may require sex adjustment. Furthermore, tau therapeutic clinical trials may need to consider sex stratifications for their primary endpoints to better estimate treatment response in men and women. From a methodological standpoint, there are implications for how tau-PET composites are created across both sexes; for instance, we would recommend avoiding the rostral middle frontal, parietal, and lateral occipital regions when creating cortical tau composites as these may introduce bias. Future studies will need to directly explore the impact of these implications particularly within the context of longitudinal study designs.

When examining the effect of menopause status or age-at-menopause in women only, we found no significant differences in tau-PET signal although the pattern of effects remained the same. This was particularly true for age-at-menopause in post-menopausal women, where age-at-menopause below 50 years was associated with numerically higher tau-PET signal in rostral middle frontal and lateral occipital regions. The window of opportunity hypothesis suggests that a shorter duration of exposure to endogenous estrogen increases risk for AD pathology.49 Earlier age at menopause, whether natural or surgically induced, increases the risk of a range of conditions, such as cardiovascular disease, psychiatric illness, osteoporosis, as well as early mortality.50 Age at premature menopause is typically considered to be between 40 and 45 years,51 much lower than the median-age cutoff defined in the current study. Thus, it is possible we underestimated the effects of age-at-menopause on tau-PET.
Given the older age-range of our sample, our analyses would have been underpowered to adopt a younger age cutoff.

The strength of this study is the large sample of middle-aged adults with both Aβ and tau-PET imaging and carefully collected menopause status information close to the time to neuroimaging. Some limitations should be acknowledged. An important consideration is our use of the age-matched male comparison group against pre- and post-menopausal groups. While this reference is not an ideal benchmark, age-matched men provide a useful tool for extricating the impact of age so as to provide an understanding of age-related tau increase that is unrelated to the menopause milieu. One interesting investigation would be of post-menopausal women on hormone therapy versus those who were not. In the current study, there were only 18 women who had any prior or current use of hormone therapy, which limited our capacity to address this question. In addition, we did not examine the impact of surgery (unilateral or bilateral oophorectomy) or circulating sex hormones (estrogen, progesterone, testosterone) in our analyses. As such, it remains unclear which component of the menopause transition may be driving our findings. Two PET scanners were used in this study necessitating smoothing harmonization procedures when combining data. We have, however, internally demonstrated that analyses with only those scanned on the GE Discovery (the camera in which the bulk of participants were scanned) provide the same pattern of results. Furthermore, examining a priori regions of the brain, while reducing the risk of a Type I error, precluded exploration of sex differences across the entire cortex in this middle-aged sample. An additional methodological consideration is the impact of sex differences in off-target binding. Smith and colleagues recently reported that off-target meningeal binding is greater in women than men for the Flortaucipir tracer. While this may be evident, our own preliminary work has suggested that it does not significantly impact sex differences in target signal in regions of interest. Finally, this sample is well-educated and predominantly Caucasian, and as such, may not be generalizable.

In summary, we show a moderating effect of menopause status on the association between sex and Aβ and tau deposition in middle-aged clinically normal adults. Post-menopausal women demonstrate higher tau-PET signal than age-matched men, as well as the pre-menopausal age-matched groups. Our study externally validates a pattern of sex divergence in tau-PET signal in the rostral middle frontal, lateral occipital, and inferior parietal regions in a cohort approximately 20 years younger compared to prior studies. Taken together, these findings suggest a role for menopause to play to increase risk for tau-PET signal in women relative to men of the same age. There remains a critical question, however, about the impact of age vs the menopause hormonal transition, specifically, on vulnerability to AD pathology in women. Future studies exploring the association between sex hormones (biomarkers of the menopausal transition), as well as age at menarche and parity and tau-PET signal are required to examine the influence of other critical transitional hormonal periods on female vulnerability to tauopathy. It would also be important to examine the impact of education and other socioeconomic status indicators to tease apart how the impact of gender may influence tau-PET signal. Finally, it will be critical to follow pre- and post-menopausal women longitudinally to more robustly assess the point at which tau accumulation diverges across the reproductive timespan.

Acknowledgments

The authors thank the participants who volunteered their valuable time to these studies. This study is funded by NIH grants AG049607, AG054076, NS017950, AG061872, AG058589, AG033040, AG054076, AG049607. The current Framingham Heart Study contract is N92019D00031-0-75. Several co-authors’ contributions were also supported by career development awards: R.F.B. is supported by a K99/R00 award from NIA (R00AG061238-03), an Alzheimer’s Association Research Fellowship (ARAF-20-675646) and philanthropic support; E.R.M. is supported by Health Research Board of Ireland (CSF-2020-011) and Alzheimer’s Association (AACSF-18-566570) awards. R.A.S. was supported by K24AG035007 award from NIA. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.

Author Contributions

Study concept and design was carried out by R.F.B., A.O., E.M., H.I.L.J., C.L., C.S., S.G., Z.R., J.M., R.E.A., K.A.J., S.S., A.S.B. Data acquisition and analysis was carried out by A.O., S.S., A.S.B. Drafting the manuscript and figures was conducted R.F.B., A.O., E.M., S.S., A.S.B.

Potential Conflict of Interest

Nothing to report.

References

1. Altmann A, Tian L, Henderson WV, Grecius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 2014;75:563–573.

2. Beydoun MA, Boueiz A, Abuogeri MS, et al. Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging 2012;33:720.e4–731.e4.
3. Neu SC, Pa J, Kukull W, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurol 2017;74:1178–1189.

4. Farrer LA, Cupples L, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997;278:1349–1356.

5. Breitner JCS, Wyse BW, Anthony JC, et al. APOE-e4 count predicts age when prevalence of AD increases, then declines: the Cache County study. Neurology 1999;53:321.

6. Liesinger AM, Graff-Radford NR, Duara R, et al. Sex and age interact to determine clinicopathologic differences in Alzheimer’s disease. Acta Neuropathol 2018;136:873–885.

7. Oveisgharan S, Arvanitakis Z, Yu L, et al. Sex differences in Alzheimer’s disease and common neuropathologies of aging. Acta Neuropathol 2018;136:887–900.

8. Buckley R, Mormino E, Rabin J, et al. Sex differences in the association between regional tau and global amyloid PET. JAMA Neurol 2019;76:542–551.

9. Damoiseaux JS, Seeley WW, Zhou J, et al. Gender modulates the APOE e4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 2012;32:8254–8262.

10. Hohman T, Dumitrescu L, Barnes L, et al. Sex-specific effects of Apolipoprotein E on cerebrospinal fluid levels of tau. JAMA Neurol 2018;75:989–998.

11. Pereira JB, Harrison TM, La Joie R, et al. Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. Eur J Nucl Med Mol Imaging 2020;1–10: 2155–2164.

12. Wisch JK, Meeker KL, Gordon BA, et al. Sex-related differences in tau postmortem emission tomography (PET) and the effects of hormone therapy (HT). Alzheimer Dis Assoc Disord 2020;35:164–168.

13. Hua X, Hobar DP, Lee S, et al. Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging 2010;31:1463–1480.

14. Koran MEI, Wagener M, Hohman TJ. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav 2017;11:205–213.

15. Skup M, Zhu H, Wang Y, et al. Sex differences in grey matter atrophy patterns among AD and aMCI patients: Results from ADNI. NeuroImage 2011;56:890–906.

16. Buckley R, Scott MR, Jacobs HI, et al. Sex mediates relationships between regional tau pathology and cognitive decline. Brain Imaging Behav 2017;11:205–213.

17. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2020,88:921–932.

18. Brinton RD, Yao J, Yin F, et al. Perimenopause as a neurological transition state. Nature reviews. Endocrinology 2015;11:393–405.

19. Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease—the gateway to precision medicine. Nat Rev Neurol 2018;14:457–469.

20. Pike CJ. Sex and the development of Alzheimer’s disease. J Neurosci Res 2017;95:671–680.

21. Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk. Neurology 2017;89:1382–1390.

22. Rahman A, Schelbaum E, Hoffman K, et al. Sex-driven modifiers of Alzheimer risk. Neurology 2020;95:e166–e178.

23. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074–1083.

24. Bove R, Secor E, Chibnik LB, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014;82:222–229.

25. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative memory study. JAMA 2004;291:2947–2958.

26. Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. The Lancet 2009;373:1233–1235.

27. Dagley A, LaPoint M, Huijbers W, et al. Harvard aging brain study: dataset and accessibility. NeuroImage 2017;144:255–258.

28. Sanchez JS, Becker JA, Jacobs HJ, et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with postmortem emission tomography. Sci Transl Med 2021;13(577): eabc0655.

29. Johnson KA, Schultz A, Betensky RA, et al. Tau postmortem emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110–119.

30. Pan T, Einstein SA, Kappadath SC, et al. Performance evaluation of the 5-ring GE discovery MI PET/CT system using the national electrical manufacturers association NU 2-2012 standard. Med Phys 2019;46:3025–3033.

31. Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting (18F)-AV-1451 tau PET data. Data Brief 2017;15:648–657.

32. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am 2011;38:425–440.

33. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924–1938.

34. Scholl M, Lockhart Samuel N, Schonhaut Daniel R, et al. PET imaging of tau deposition in the aging human brain. Neuroen 2016;89:971–982.

35. Lowe VJ, Wiste HJ, Senjem ML, et al. Widespread brain tau and its association with ageing. Brain Aging 2017;141:271–287.

36. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metabol 2003;88:2404–2411.

37. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011;77:461–468.

38. Gannon O, Robison L, Custozzo A, Zuloaga K. Sex differences in risk factors for vascular contributions to cognitive impairment & dementia. Neurocom Int 2019;127:38–55.

39. Palfia P, Rippon B, Tahmi M, et al. Sex differences in in vivo tau neuropathology in a multicentric sample of late middle-aged adults. Neurobiol Aging 2021;103:109–116.

40. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.

41. Riley KP, Snowdon DA, Markesbery WR. Alzheimer’s neuropathology and the spectrum of cognitive function: findings from the nun study. Ann Neurol 2002;51:567–577.

42. La Joie R, Visani AV, Lesman-Segev OH, et al. Association of APOE4 with tau-and amyloid-PET. Neurology 2020;96:e650–e661.

43. Tang-Wai DF, Graff-Radford N, Boeve B, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168–1174.

44. Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009;73:1571–1578.

45. Miller ZA, Rosenberg L, Santos-Santos MA, et al. Prevalence of mathematical and visuospatial learning disabilities in patients with posterior cortical atrophy. JAMA Neurol 2018;75:728–737.
46. Cho H, Choi JY, Lee SH, et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer’s disease. Neurobiol Aging 2017;53:103–111.

47. Franzmeier N, Dewenter A, Frontzkowski L, et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease. Sci Adv 2020;6(48):eabd1327.

48. Jack CR, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87:539–547.

49. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011;1379:188–198.

50. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061–1066.

51. Shuster LT, Rhodes DJ, Gostout BS, et al. Premature menopause or early menopause: long-term health consequences. Maturitas 2010;65:161–166.

52. Schmidt ME, Chiao P, Klein G, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement 2015;11:1050–1068.

53. Smith R, Strandberg O, Leuzy A, et al. Sex differences in off-target binding using tau positron emission tomography. NeuroImage: Clin 2021;31:102708.

54. Scott MR, Edwards NC, Properzi MJ, et al. Extraneous neuroimaging factors do not contribute to sex differences in flortaucipir signal: analysis of skull binding and partial volume effects. Alzheimer’s Dement 2021;17(S1):e056051.